<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229147</url>
  </required_header>
  <id_info>
    <org_study_id>RT2019-09</org_study_id>
    <nct_id>NCT04229147</nct_id>
  </id_info>
  <brief_title>Ledderhose Disease - Long Term Effects of Radiotherapy Treatment. LedRad LTE - Study</brief_title>
  <official_title>Ledderhose Disease - Long Term Effects of Radiotherapy Treatment. LedRad LTE - Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the LedRad LTE study is to determine the current complaints, late side effects and
      satisfaction of patients who were treated with radiotherapy for Ledderhose disease at least
      two years ago.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Current pain</measure>
    <time_frame>at least 2 years after treatment</time_frame>
    <description>Determine pain with the numeric rating scale. A 11-point pain scale ranging from 0=no pain to 10=worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worst pain</measure>
    <time_frame>at least 2 years after treatment</time_frame>
    <description>Determine pain with the numeric rating scale. A 11-point pain scale ranging from 0=no pain to 10=worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>at least 2 years after treatment</time_frame>
    <description>Assess the impact on quality of life of the treatment with radiotherapy for this study population with the EURO-Qol-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late side effects of treatment</measure>
    <time_frame>at least 2 years after treatment</time_frame>
    <description>Is treatment still effective and/or are there any (unknown) side effects of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with radiotherapy treatment for Ledderhose disease</measure>
    <time_frame>at least 2 years after treatment</time_frame>
    <description>Determine patient satisfaction with the radiotherapy treatment for Ledderhose disease using a self developed questionnaire</description>
  </secondary_outcome>
  <enrollment type="Actual">68</enrollment>
  <condition>Ledderhose Disease</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Patients who received a total dose of 30 Gy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Ledderhose disease and treated with radiotherapy at least 2 years ago at the
        UMCG
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients treated with radiotherapy for Ledderhose disease at the UMCG at least 2 years ago
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 5, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Roel Steenbakkers</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Pain</keyword>
  <keyword>Side effect</keyword>
  <keyword>Satisfaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromatosis, Plantar</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

